Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global embryo biopsy medium market was valued at USD 57.8 million in 2024 and is projected to reach USD 77.7 million by 2031, exhibiting a CAGR of 4.4% during the forecast period. This growth is primarily driven by increasing demand for preimplantation genetic testing (PGT) procedures in assisted reproductive technology (ART) clinics worldwide.
Embryo biopsy medium is a specialized solution used during blastomere biopsy procedures at the cleavage stage (day 3 embryos) for preimplantation genetic diagnosis (PGD). The fluid provides optimal osmotic pressure and ion concentrations to maintain embryo viability during the delicate biopsy procedure. Major manufacturers include CooperSurgical, Vitrolife, FUJIFILM Irvine Scientific, and Kitazato, who collectively hold over 65% of the market share.
The market shows strongest growth in Asia Pacific regions (CAGR 5.8%) where IVF adoption is rapidly increasing, compared to North America (CAGR 3.9%) and Europe (CAG 4.2%). This correlates with the fact that China and India collectively performed over 1.8 million ART cycles in 2023, representing approximately 40% of global ART procedures.
Recent technological advancements include the development of ready-to-use formulations that reduce preparation time from 45 minutes to under 10 minutes, and improved buffering systems that maintain pH stability for up to 45 minutes outside incubator conditions. These improvements have contributed to the 18% year-on-year growth in emerging markets.
Market growth is primarily constrained by the high cost of single-use consumables (approximately USD 350-500 per procedure) and limited reimbursement policies in developing countries. However, increasing insurance coverage for genetic testing in developed markets continues to drive adoption.
The market shows a clear trend toward standardized, regulated products following the implementation of EU IVDR 2022 and US FDA guidance on human cell and tissue products. All major manufacturers now offer CE-marked and FDA-cleared products, with 92% of US fertility clinics using regulated products compared to 78% in 2020.
Looking forward, market growth is expected to accelerate as next-generation sequencing costs decrease and multi-omics approaches become more integrated into routine IVF care. The global shift toward comprehensive embryo assessment will likely increase the utilization of biopsy media and related products.
Rising Demand for Preimplantation Genetic Testing
The increasing adoption of preimplantation genetic testing (PGT) in assisted reproductive technology (ART) is driving demand for specialized embryo biopsy media. As more couples opt for comprehensive embryo screening, the need for high-quality biopsy media that ensures cell viability during the procedure has become paramount.
Advancements in Single-Cell Genomics
Recent breakthroughs in single-cell genomic analysis have created new opportunities for embryo biopsy applications. The ability to extract and analyze genetic material from a single cell has revolutionized prenatal diagnostics, driving demand for optimized biopsy media that maintains cellular integrity during the procedure.
The global IVF market is projected to reach $36.2 billion by 2030, with embryo biopsy procedures growing at a compound annual growth rate of 9.8%.
Growing infertility rates worldwide, particularly in developed nations, are contributing to increased adoption of ART procedures. With approximately 48 million couples experiencing infertility globally, the demand for advanced embryo biopsy techniques and supporting media continues to expand significantly.
MARKET CHALLENGES
High Cost of Specialized Media
The development and production of specialized embryo biopsy media requires significant investment in research and quality control. These costs are often passed on to fertility clinics and patients, creating economic barriers to widespread adoption in cost-sensitive markets. The average cost of a single vial of premium biopsy medium can exceed $500, making it challenging for smaller clinics to maintain adequate inventory.
Other Challenges
Regulatory Hurdles and Standardization
Different countries have varying regulatory requirements for assisted reproductive technology products, creating challenges for manufacturers seeking global distribution. The lack of international standardization in embryo biopsy procedures also presents challenges for media developers who must account for different clinical practices and regulatory environments.
Limited Skilled Practitioners
The complex technique of embryo biopsy requires highly trained embryologists and embryologists, creating a bottleneck in market growth. There are currently only approximately 5,000 qualified embryologists worldwide who are proficient in advanced biopsy techniques, limiting the speed of market expansion in developing regions where training infrastructure is still developing.
Emerging Markets Expansion
Developing countries with growing middle-class populations are increasingly investing in advanced fertility treatments. Countries such as Brazil, India, and Turkey are experiencing rapid growth in their fertility clinics, creating new markets for embryo biopsy media manufacturers. The Asia-Pacific region alone is expected to account for 38% of the market growth by 2028, representing a significant opportunity for market expansion.
Integration with AI and Automation
The integration of artificial intelligence and robotic automation in embryo biopsy procedures presents significant growth opportunities. Automated systems can standardize the biopsy process, reduce human error, and increase throughput. Recent studies show that AI-assisted embryo selection can improve success rates by up to 15%, creating demand for compatible media and systems.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Single-step biopsy mediums are gaining traction due to their operational simplicity and reduced risk of contamination during the embryo biopsy process, while multi-component formulations offer superior customization for specific embryo types and clinical scenarios. |
| By Application |
|
Preimplantation genetic testing (PGT) continues to dominate the application landscape due to rising demand for comprehensive embryo screening, while cryopreservation applications are growing as clinics adopt more sophisticated embryo preservation techniques requiring specialized media formulations. |
| By End User |
|
Fertility clinics and IVF centers remain the primary end-users due to the direct application in assisted reproductive technologies, while academic institutions contribute significantly to innovation through research on improved biopsy techniques and media formulations. |
Companies Enhance Product Portfolios to Capture Market Share in Growing Embryo Biopsy Medium Segment
CooperSurgical Inc. (United States) leads the market with its comprehensive portfolio of embryo biopsy products and strong distribution network across North America and Europe, while Vitrolife AB (Sweden) maintains strong presence with its specialized media formulations for pre-implantation genetic testing applications.
FUJIFILM Irvine Scientific, Inc. (United States) and Thermo Fisher Scientific Inc. (United States) compete through advanced media formulations and global distribution networks, particularly capturing significant market share in Asia-Pacific regions.
Recent expansions include FUJIFILM's new manufacturing facility in China, strengthening their supply chain for Asian markets, while CooperSurgical acquired several smaller specialized companies to expand their reproductive health portfolio in 2023.
Market leaders continue investing in R&D partnerships with major IVF clinics and research institutions, focusing on developing next-generation media with improved stability and consistency for critical embryo biopsy procedures.
List of Key Embryo Biopsy Medium Companies ProfiledCooperSurgical Inc. (United States)
CooperSurgical Inc. (United States)
Vitrolife AB (Sweden)
FUJIFILM Irvine Scientific, Inc. (United States)
Thermo Fisher Scientific Inc. (United States)
Irvine Scientific (United States)
The global embryo biopsy medium market is experiencing significant growth, primarily driven by the increasing adoption of Preimplantation Genetic Testing for Aneuploidy (PGT-A) in IVF clinics. With infertility rates rising globally, particularly in developed regions, the demand for advanced embryo screening techniques has accelerated. Market analysis indicates a compound annual growth rate (CAGR) of 12.3% over the past three years, with the market expected to reach $220 million by the end of the current fiscal year. This growth is largely attributed to technological advancements in biopsy techniques that minimize embryo damage while maintaining high diagnostic accuracy.
Other TrendsShift Toward Single-Cell Biopsy Protocols
Recent innovations have focused on minimizing the number of cells required for accurate genetic testing, with many manufacturers developing specialized media that support single-cell biopsy procedures. This trend aligns with the growing emphasis on embryo viability preservation, where reducing biopsy-induced stress remains a key priority. Current data indicates that over 65% of IVF clinics in North America have adopted single-cell biopsy protocols, supported by optimized media formulations that enhance cell recovery and viability post-biopsy.
Market penetration varies significantly by region, with North America holding the largest market share at 42%, followed by Europe at 31% and Asia-Pacific rapidly catching up with 27% annual growth. The disparity is primarily attributed to differences in regulatory frameworks, reimbursement policies, and availability of advanced medical infrastructure. Emerging markets in Southeast Asia and Latin America show the highest growth potential, with projected growth rates exceeding 18% annually as accessibility to advanced IVF treatments improves in these regions.
Regional Analysis: Embryo Biopsy Medium MarketEurope
Europe maintains a strong position in the Embryo Biopsy Medium Market, characterized by high standards of quality control and regulatory compliance. The region benefits from well-established biomedical research institutions that contribute to ongoing product development and refinement. Collaborative initiatives between European countries facilitate standardization of protocols and best practices, while the presence of multinational pharmaceutical companies ensures continued investment in research and development. The region's emphasis on ethical considerations in assisted reproduction also influences product development toward more ethical and sustainable solutions.
Asia-Pacific
The Asia-Pacific region demonstrates rapidly growing capabilities in embryo biopsy medium technologies, driven by increasing healthcare investments and growing medical expertise. Countries like Japan and South Korea lead in technological adoption, while emerging economies show accelerated growth through technology transfer and international partnerships. The region benefits from large patient populations seeking fertility treatments, driving demand for advanced technologies. Regional collaborations and knowledge sharing contribute to faster adoption of newer techniques compared to other regions.
Latin America
Latin America shows consistent growth in embryo biopsy medium utilization, supported by improving regulatory frameworks and increasing specialist training programs. The region benefits from proximity to North American markets, facilitating technology transfer and knowledge exchange. Growing medical tourism from within the region creates additional demand for high-quality products and services. Countries with more developed healthcare systems serve as regional hubs for training and technology adoption, while regional partnerships help address specific challenges like supply chain optimization.
Middle East & Africa
The Middle East and African regions show developing capabilities in embryo biopsy medium technologies, with significant variation between countries. Nations with stronger healthcare infrastructure show faster adoption, while others benefit from international partnerships and training programs. Specialized centers in major urban areas serve as regional hubs for advanced procedures, with growing interest in developing local expertise rather than relying on medical tourism. International collaborations bring training opportunities and technology transfer, though infrastructure development remains an ongoing process in many areas.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252031. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global embryo biopsy medium market was valued at USD 57.8 million in 2024 and is expected to reach USD 77.7 million by 2031.
-> The market is projected to grow at a CAGR of 4.4% during the forecast period 2024-2031.
-> Key players include CooperSurgical, Vitrolife, FUJIFILM Irvine Scientific, Kitazato, Reprobiotech Corp, and Chengdu AIVFO Biotech, with major manufacturers holding over 65% market share.
-> Key growth drivers include increasing demand for preimplantation genetic testing (PGT) in assisted reproductive technology (ART) clinics worldwide, with China and India performing over 1.8 million ART cycles annually.
-> Asia-Pacific shows the strongest growth (CAGR 5.8%) compared to North America (3.9%) and Europe (4.2%).
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates